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a b s t r a c t
Along with the tri-lineage of bone, cartilage and fat, human mesenchymal stem cells (hMSCs) retain
neural lineage potential. Multiple factors have been described that inﬂuence lineage fate of hMSCs
including the extracellular microenvironment or niche. The niche includes the extracellular matrix (ECM)
providing structural composition, as well as other associated proteins and growth factors, which
collectively inﬂuence hMSC stemness and lineage speciﬁcation. As such, lineage speciﬁc differentiation
of MSCs is mediated through interactions including cell–cell and cell–matrix, as well as through speciﬁc
signalling pathways triggering downstream events. Proteoglycans (PGs) are ubiquitous within this
microenvironment and can be localised to the cell surface or embedded within the ECM. In addition, the
heparan sulfate (HS) and chondroitin sulfate (CS) families of PGs interact directly with a number of
growth factors, signalling pathways and ECM components including FGFs, Wnts and ﬁbronectin. With
evidence supporting a role for HSPGs and CSPGs in the speciﬁcation of hMSCs down the osteogenic,
chondrogenic and adipogenic lineages, along with the localisation of PGs in development and
regeneration, it is conceivable that these important proteins may also play a role in the differentiation
of hMSCs toward the neuronal lineage. Here we summarise the current literature and highlight the
potential for HSPG directed neural lineage fate speciﬁcation in hMSCs, which may provide a new model
for brain damage repair.
& 2014 Elsevier Inc. All rights reserved.
Human mesenchymal stem cells: characterisation and lineage
potential
Stem cells possess unique characteristics that distinguish them
from other cell types, speciﬁcally, these cells are unspecialised,
capable of self-renewal, and found in both the embryo and adult.
Together with their extensive capacity for self-renewal, stem cells
display a broad potential for giving rise to diverse differentiated
progenies as well as being highly malleable, displaying a high
degree of plasticity (Minguell et al., 2001). Based on differentiative
ability, stem cells are classiﬁed into three main types: totipotent,
cells that can divide to produce all cells in an organism, these
include zygotes; pluripotent, cells that can be differentiated into
any of the three germ layers (endoderm, ectoderm or mesoderm);
and ﬁnally multipotent stem cells, these cells can produce multiple
cell types of a limited number of lineages. There are multiple
sources of adult stem cells including, but not limited to, haema-
topoietic stem cells, neural stem cells and mesenchymal stem cells
(MSCs). During lineage commitment, stem cells leave their niche
to circulate in the blood stream and develop lineage-speciﬁc
characteristics (Erices et al., 2000; Fernandez et al., 1997; Hu
et al., 1995; Reading et al., 2000; Shields and Andrews, 1998; Siena
et al., 1989), including homing in on an appropriate new micro-
environment or tissue speciﬁc niche in which to undergo their
differentiation program (Tavassoli and Minguell, 1991; Watt and
Hogan, 2000).
Human mesenchymal stem cells (hMSCs) are generally derived
from the bone marrow (Mackay et al., 1998; Pittenger et al., 1999),
but can also be sourced from other tissues including umbilical cord
blood, adipose tissue (Cunningham et al., 2006), salivary glands
(Rotter et al., 2008) and from organs such as the gut (Lanzoni et al.,
2009). As MSCs are derived from different sources, their viability,
yield and differentiation potential vary, with evidence that the
source as well as method of isolation inﬂuences this potential
(reviewed in (Hass et al., 2011; Ragni et al., 2013)). It is generally
accepted that MSCs from all sources give rise to a variety of
mesenchymal phenotypes including bone, cartilage, muscle, liga-
ment, tendon, adipose and stroma (Friedenstein et al., 1987;
Haynesworth et al., 1992; Kuznetsov et al., 1997). In addition,
these cells can also give rise to non-mesenchymal cells including
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neural cells. The multipotentiality of hMSCs, along with their easy
isolation and expansion in vitro, and their high ex vivo expansive
potential make these cells an attractive therapeutic tool in a wide
range of clinical applications (Minguell et al., 2001). Currently
MSCs are identiﬁed and characterised by a combination of in vitro
morphological, immune phenotypical and differentiative charac-
teristics including lineage capacity (da Silva Meirelles et al., 2008;
Kolf et al., 2007; Lindner et al., 2010). These marker combinations
deﬁne what is commonly referred to as their “stemness” or multi-
lineage potential.
A number of cell surface markers analysed by both ﬂow
cytometry and immunocytochemistry are routinely used to char-
acterise hMSCs. Commonly, to conﬁrm hMSC stemness and lineage
potential, cell populations should be 495% positive for some
combination of CD29, CD44, CD73, CD90 and CD105 and o2%
positive for CD11b, CD14, CD19, CD34, CD45, CD79α and HLA-DR
(Lindner et al., 2010; Sadan et al., 2009). Although MSCs have high
expansive potential, when propagated in vitro, the cells are not
immortal with limited growth potential and number of population
doublings. We have expanded several hMSC populations for 420
passages (460 days in culture and 450 population doublings)
with populations derived from multiple donors demonstrating
similar growth patterns. These commercially available hMSCs
were obtained (Lonza, Australia) after isolation from the bone
marrow of the posterior iliac crest of normal donors and when
expanded remain positive for MSC lineage markers (summarised
in Table 1, Fig. 1).
Basal nutrients, cell density, spatial organisation, mechanical
forces, growth factors and cytokines all inﬂuence MSC lineage
potential (Pittenger et al., 1999) with differentiation down the tri-
lineages (bone, cartilage and fat) often used to conﬁrm hMSC
lineage potential. MSCs produce several haematopoietic and non-
haematopoietic growth factors, interleukins and chemokines,
many of which are constitutively produced while others are only
expressed after stimulation (Haynesworth et al., 1996). Of parti-
cular relevance is CD44 (Conget and Minguell, 1999; Pittenger
et al., 1999), a receptor for various ligands including hyaluronan
and osteopontin, which plays a central role in the organisation of
the ECM in the marrow and bone respectively (Minguell, 1993).
Evidence that MSCs actively participate in the dynamic marrow
microenvironment is strengthened by data demonstrating their
production of a vast array of matrix molecules, including ﬁbro-
nectin, laminin, collagen, and proteoglycans (Pittenger et al., 1999),
along with their expression of several counter-receptors associated
with matrix– and cell–cell interactions. Additional plasticity for
differentiation of MSCs into cardiogenic and myogenic as well as
non-mesodermal cell types such as neuronal cells has been
proposed (Ferrari et al., 1998; Hakuno et al., 2002; Makino et al.,
1999). With several studies conﬁrming neuronal differentiation of
human MSCs in vitro via intermediate neural stem cell (NSC) -like
spheres or direct terminal differentiation (Alexanian, 2010;
Hermann et al., 2004), neural differentiation of MSCs in vivo has
been observed following injection of these cells into the lateral
ventricle and subsequent cell migration monitored and traced
throughout the forebrain and cerebellum (Kopen et al., 1999;
Reyes and Verfaillie, 1999). The use of intermediate NSC-like
spheres allows differentiation down each of the three neural
lineages rather than the restricted differentiation to neurons and
astroglia achieved through direct terminal differentiation
(Hermann et al., 2006). The most successful method generated
by Alexanian and colleagues (2010) for direct terminal differentia-
tion utilises simultaneous treatment of hMSCs with inhibitors of
DNA methylation and histone deacetylation as well as pharmaco-
logical agents to increase intracellular cAMP (Alexanian, 2010). In
contrast, in conversion via neuroprogenitor-like cells, spheres are
produced in appropriate growth conditions including uncoated
ﬂasks and the presence of EFG/FGF-2. Neuronal cells with reduced
expression of proneural genes (SOX1, OTX1, NeuroD1 and Neu-
rog2) and increased levels of mature neural markers (GFAP, MBP
and TH) result after the removal of EGF and FGF-2 from the sphere
media, plating of cells onto poly-L-lysine coated slides and sub-
sequent addition of BDNF and retinoic acid (Hermann et al., 2004).
The successful differentiation to neural-like cells is demonstrated
via the detection of neural markers, through immunocytochem-
istry and gene expression, as well as the secretion of neurotrophic
factors (BDNF, GDNF) required for the survival and growth of
neuronal cells (Alexanian, 2010). In addition, the intermediate
sphere-like structures produced during the process of differentia-
tion have been found to express high levels of early neuroecto-
dermal (NeuroD1, Neurog2, MSI1) markers as well as the loss of
expression of mesodermal stromal cell markers (Fibronectin)
(Hermann et al., 2004). The derived NSC-like cells differentiated
into the three neural lineages (astroglia, oligodendroglia and
neurons) exhibit both morphological and functional neural cell
characteristics (Hermann et al., 2004).
Role of the stem cell niche – why is it important?
The local microenvironment, or niche, plays a central role in
cell regulation and development. A major component of the niche
is the extracellular matrix (ECM), which supplies critical biochem-
ical and physical signals along with structural stability to initiate
and sustain cellular functions (Chen, 2010). The ECM supports a
rich signalling environment important for a range of develop-
mental decisions (Rozario and DeSimone, 2010) including lineage
speciﬁcation, through regulation of growth factor interactions
between the ECM and the cell, subsequently controlling cell
replication and differentiation (Chen, 2010). Distinct matrix pro-
teins inﬂuence the speciﬁcity of the ECM via their contribution to
the architecture of the ECM, their ability to interact with growth
factors and MSCs themselves or by their ability to remodel matrix
constituents (Chen, 2010). As such, ECM structure and conforma-
tion mediates physical linkages with the cytoskeleton and the
bidirectional ﬂow of information between the extracellular and
intracellular compartments (Rozario and DeSimone, 2010).
Cells within the niche are centrally involved in the dynamic
assembly and remodelling of the ECM (Rozario and DeSimone,
2010) where effectively the ECM functions as an adhesive sub-
strate to direct migratory cells and to establish concentration
gradients for haptotactic migration. By providing structure, the
ECM deﬁnes tissue boundaries, provides integrity and elasticity to
Table 1
Mesenchymal stem cell marker panel.
Marker Gene Symbol Gene Lineage þve/ve
CD29 ITGB1 Integrin β1 Myoepithelial/neural þ
CD44 CD44 CD44 antigen (Indian Blood Group) MSC/epithelial þ
CD45 PTPRC Protein tyrosine phosphotase receptor Type C Hematopoietic progenitors 
CD90 THY1 Thy 1 cell surface antigen Haematopoietic/neural/lymphoid þ
CD105 ENG Endoglin MSC/endothelial progenitors/activated macrophages þ
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developing organs, and serves as a degradable barrier to invasive
cells during development and disease. The ECM can present
growth factors to receptors, controlling spatial distribution and
sequester growth factors for controlled release, maintaining mor-
phogen gradients and niche speciﬁc interactions. In addition, the
ECM also plays a role in mechanical signalling, inﬂuencing cell
differentiation and downstream intracellular signalling (Rozario
and DeSimone, 2010).
The “sensing” of embedded information in the ECM by specia-
lised receptors at the cell surface (e.g. integrins, syndecans) affects
cellular behaviours including adhesion, as well as cell polarity,
migration and other intracellular signals regulating cell survival,
proliferation and differentiation (Rozario and DeSimone, 2010).
The most familiar developmental function attributed to the ECM is
cell migration. Cell locomotion is the result of dynamic ECM-
integrin binding interactions known to facilitate cycles of cell
adhesion and release to or from substrates as occurs in neuronal
migration during the development of the cerebellum (Rozario and
DeSimone, 2010). The ECM can also bind soluble/secreted factors
and maintain them in extracellular spaces functioning as a sub-
strate repository. The consequence of all of these interactions may
restrict or promote access of ligands to cognate cell-surface
receptors, modulate the spatial distribution of a diffusible mor-
phogens, or sequester factors for subsequent release (Rozario and
DeSimone, 2010).
A number of studies have also demonstrated the ability of
different niches to support neural phenotypes in vitro. In a study
by Mezey et al., transplanted mouse bone marrow cells were
shown to migrate from the bone marrow to the brain and
differentiate into cells expressing neural antigens suggesting the
bone marrow as an alternative source of neural progenitor cells
(Mezey et al., 2000). In addition, cells derived from Ewing's
sarcoma (ES, metastatic bone marrow) were differentiated to
neuronal cells through the addition of cholera toxin B (CTB) or
5-bromo-2'-deoxyuridine (BrdU) (Ohta et al., 1991). Following
treatment with CTB, the cells exhibited a gradual increase in
neural marker expression demonstrating modiﬁcation of the
localised in vitro niche and the cell's interaction with it can
inﬂuence neuronal fate speciﬁcation of MSCs (Ohta et al., 1991).
Proteoglycans – why they like to be involved in everything
Proteoglycans (PGs) are major constituents of the ECM, char-
acteristically comprised of a core protein to which a series of
glycosaminoglycan (GAG) side chains attach at speciﬁc sites
(Hacker et al., 2005). GAGs are unbranched, usually high-
molecular weight proteins consisting of a repeating disaccharide
backbone (Hacker et al., 2005). Depending on the disaccharide
structure of the chain, GAGs can be grouped into chondroitin/
dermatan sulphate (CS/DS), heparan sulphate (HS) and keratin
sulphates (KS) with PGs able to carry a number of chains from any
of these groups individually or in combination (Bandtlow and
Zimmermann, 2000; Lindahl et al., 1998). Due to their ubiquitous
nature, PGs structurally and functionally inﬂuence cell prolifera-
tion, differentiation and gene expression (Lamoureux et al., 2007;
Oohira et al., 2000) through their extracellular or cell surface
localisation (Iozzo, 1998; Perrimon and Bernﬁeld, 2000). PGs have
been identiﬁed as important extracellular modulators of protein
gradient formation and signal transduction (Hacker et al., 2005)
and include the heparan sulphate (HS) (membrane bound glypi-
cans, syndecans) and chondroitin sulphate (CS) proteoglycans
(matrix localised) (Hacker et al., 2005). HS chains interact with a
large number of ligands including growth factors and morphogens
(FGF, Wnts), their receptors (FGFRs), and ECM structural molecules
(ﬁbronectin) where they regulate activity, as well as ligand
stability (Habuchi et al., 2004; Hacker et al., 2005). HS and CS
GAG chains are created by an elaborate post-translational bio-
synthesis (Ling et al., 2006; Sugahara and Kitagawa, 2002), which
occurs on genetically distinct acceptor core proteins within the
Golgi, followed by rapid translocation to the cell surface
(Hardingham and Fosang, 1992) resulting in highly sulfated vari-
able length side chains attached to a core protein (Bandtlow and
Zimmermann, 2000; Sugahara and Kitagawa, 2002). The introduc-
tion of N- and O-sulfation at different points combine to produce a
combination of chain length and sulfation pattern that confers
biological diversity onto the HS and CS chains and subsequently
the core proteins to which they are linked (Habuchi et al., 2004;
Lindahl et al., 1998).
GAG production and subsequent sulfation appears to be tem-
porally coordinated with substrate recognition and HS chain
modiﬁcation generally dependent on structural modiﬁcations
introduced in previous reactions (Lindahl et al., 1989; Salmivirta
et al., 1996) (Fig. 2). In addition, there is increasing evidence that
the cell- and tissue-speciﬁc expression of the modifying enzymes
and the formation of specialised enzyme complexes control the
microstructural domains within GAG chains. These microstruc-
tures participate in the binding of HS to speciﬁc growth factors,
protease inhibitors, and ECM molecules inﬂuencing overall func-
tion of PGs (Bandtlow and Zimmermann, 2000; Lindahl et al.,
1998). Importantly, the speciﬁcity of interactions between ligands
and HS is inﬂuenced by the ﬁne structure of each HS, primarily its
sulfation pattern (Habuchi et al., 2004). A number of detailed
reviews outline this complex biosynthesis (Habuchi et al., 2004;
Lindahl et al., 1989; Salmivirta et al., 1996); however, with PGs
associated with intracellular compartments, cell surface, ECM and
basement membranes in almost all adult tissues, it is thought that
the highly variable protein structure confers speciﬁc functions for
different members of the PG family (Lamoureux et al., 2007). In
addition to cell surface expression, CSPGs are a major component
of the brain ECM, and contribute to maintaining localised structural
integrity and cellular function. Their role in brain development is
Fig. 1. Representative ICC images of hMSC-2 at Pþ7, positive for MSC lineage markers. (A) CD44 (ab6124) 1/200 dilution (B) CD29 (ab52971) 1/200 dilution (C) CD105
(ab44967) 1/1000 dilution. Secondary antibodies were (yellow) Chromeo 546 and (green) Chromeo 488 at 1/250 dilution for 2 h. Fluoroshield mounting medium with DAPI
(ab104139) was used to stain nuclei (blue).
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well known and has been extensively investigated (Maeda, 2010;
Margolis and Margolis, 1997; Oohira et al., 2000; Yamaguchi, 2000,
2001); however, the role of PGs in stem cell (mesenchymal or
neural) proliferation and lineage fate determination is as yet
unknown.
Heparan Sulfate Proteoglycans
Heparan Sulphate Proteoglycans (HSPGs) play important roles
in biological processes at the cell–tissue–organ interface and in
cell growth and development (Perrimon and Bernﬁeld, 2000),
angiogenesis (Sasisekharan et al., 1997), viral invasion (Shukla
et al., 1999) and anticoagulation (Petitou et al., 1999). In terms of
localisation, the HSPGs perlecan, agrin and collagen XVIII are
found in basement membranes (Iozzo, 1998), while those belong-
ing to the glypican and syndecan families are bound to the cell
surface (Filmus and Selleck, 2001; Zimmermann and David, 1999).
As HS functions as a cofactor in cell adhesion, motility, prolifera-
tion, differentiation, and tissue morphogenesis by interacting with
diverse protein ligands through speciﬁc saccharide sequences
(Bernﬁeld et al., 1999; Rosenberg et al., 1997; Salmivirta et al.,
1996), numerous proteins involved in organising the basic body
plan depend upon HS for their function (Carey, 1997). With HS
chains responsible for much of the biological role of HSPGs, their
core proteins have evolved to maximise their efﬁciency in their
supportive roles (Bernﬁeld et al., 1999). Interestingly, HS chains on
the same core protein from different cell types show consistent
and reproducible structural differences including variations in
domain number, spacing, size and O-sulfation pattern (Bandtlow
and Zimmermann, 2000) suggesting tissue and micro-
environmental (niche) speciﬁc synthesis and function. An active
hypothesis for the diverse roles that cell surface HS plays in
multiple cellular events includes the catalysis of molecular inter-
actions at the cell surface (Lander, 1998) with a large number of
proteins including heparin-binding growth factors FGFs, VEGFs,
TGF-β and PDGF.
The glypican family of HSPGs are linked to the cell surface
through a glycosyl-phosphatidyl-inositol (GPI) anchor (Filmus and
Selleck, 2001) resulting in membrane localisation. The six glypi-
cans share an insertion site for HS chains, which seems to be
restricted to the last 50 amino acids at the C-terminus, locating the
HS chains close to the cell membrane (Veugelers et al., 1999). This
localisation suggests a role for HS in mediating glypican interac-
tion with other cell–surface molecules including growth factor
receptors (Filmus et al., 2008). It has been proposed that the
glycolipid-enriched cell-membrane subdomains of the glypicans
facilitate selective protein–protein interactions that establish tran-
sient cell-signalling platforms (Hancock, 2006). While predomi-
nantly bound to the cell membrane, glypicans can also be localised
in the extracellular environment and in the cytoplasm (Capurro
et al., 2003). In vivo evidence indicates that the main function of
membrane-attached glypicans is to regulate the signalling of
Wnts, Hedgehogs, FGFs and bone morphogenetic proteins (BMPs)
(Filmus et al., 2008). Glypicans can stimulate or inhibit signalling
activity through interactions with morphogens and receptors. For
example in Wnt signalling, glypicans facilitate or stabilise the
interaction of Wnt with its receptor Frizzled (Filmus et al., 2008),
in contrast, glypican-3 has recently been reported to inhibit
Hedgehog protein signalling during development by competing
with Patched, the Hedgehog receptor, for Hedgehog binding. This
regulatory activity of glypicans in the Wnt, Hedgehog and BMP
signalling pathways has been reported to be only partially depen-
dent on the HS chains (Filmus et al., 2008). The other main family
of HS core proteins is the syndecans. The syndecan family of four
core PGs, are type I transmembrane proteins (Bernﬁeld et al., 1992;
Carey, 1997; Rapraeger and Ott, 1998) with a short cytoplasmic
domain, a single transmembrane domain and an extracellular
domain that has attachment sites for three to ﬁve chains
(Tkachenko et al., 2005) allowing syndecans to carry both HS
and CS chains (Elenius and Jalkanen, 1994). All four syndecans are
expressed in both the developing brain and adult brain tissue
(Bandtlow and Zimmermann, 2000).
hMSCs, PGs and cell fate
The differentiation of MSCs toward speciﬁc lineages in vitro
requires seeding the cells at appropriate densities, with both cell
density and cell shape playing important roles in lineage commit-
ment. Engler et al. (2006) demonstrated that MSC lineage speci-
ﬁcation is inﬂuenced by ECM substrate stiffness. In that study,
MSCs plated on collagen gels “tuned” to mimic the elasticity of the
brain, muscle or bone microenvironments gave rise to neurogenic,
myogenic and osteogenic cells, respectively (Engler et al., 2006).
Speciﬁcally, ECM substrates can be designed to promote particular
cellular shapes (rounded, elongated or spread) to inﬂuence cell
fate, with conditions favouring elongated cells resulting in MSCs
differentiated toward smooth muscle cells, whereas conditions
favouring a round shape inhibited smooth muscle differentiation
(Engler et al., 2006). Manipulating surface topography and con-
trolling cell attachment, shape and polarity to mediate MSC
differentiation highlight the remarkable lineage potential of these
cells. With lineage speciﬁcation dependent on cell morphology, it
is not surprising that cell density mediates the cells' ability to
spread or contract against a surface. Lower cell densities have been
shown to allow hMSCs to display a spread shape, favouring
osteogenic differentiation with higher cell densities used to con-
dense cells to become round, driving them toward adipogenesis
(Ling et al., 2009; Engler et al., 2006). Indeed, well spread cells
Fig. 2. Schematic outlining the complex biosynthesis process required to synthe-
sise HSPGs and CSPGs. The complexity of length and sulfation pattern incorporated
into the side chains during this process determines the ability of HSPGs and CSPGs
to interact with binding partners triggering downstream signalling cascades.
(modiﬁed from Hancock, 2006).
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express calcifying bone proteins common in osteoblasts, in contrast
poorly spread cells develop large lipid deposits typical of adipocytes
(Engler et al., 2006) and are limited in their spreading and tension.
In addition, the expression levels of Wnt-signalling molecules in
MSCs have been reported to be inﬂuenced by cell density (Gregory
et al., 2003) with mesenchymal condensation, characterised by
increased cell density and cell–cell adhesion, deemed to be a critical
step in initiating chondrogenesis (Tuan, 2003).
Clearly the ECM impacts a number of cellular functions critical
for normal development and morphogenesis (Rozario and
DeSimone, 2010). As growth factors can bind directly to the
ECM, become sequestered in the matrix, and ultimately be
liberated by either proteolytic degradation of the matrix or by
cell-generated forces, the ECM plays a central role in regulating
stem cell differentiation (Rozario and DeSimone, 2010). New and
more direct connections between the ECM and cell fate speciﬁca-
tion have recently been identiﬁed. As an example, laminin has
been shown to promote speciﬁc fates in different tissues (Rozario
and DeSimone, 2010) with mouse and human NSC precursors able
to differentiate into neurons, astrocytes and speciﬁc glia on
laminin but not on ﬁbronectin (Flanagan et al., 2006). However,
not all laminin isoforms are competent to induce cell differentia-
tion suggesting that there may indeed be exquisite speciﬁcity in
how the ECM inﬂuences these cellular processes (Rozario and
DeSimone, 2010). Weihe et al. (1991) investigated the neural
lymphoid niche, noting common transmitters and neuropeptides
characteristic of all lymphoid tissues and organs including the
bone marrow, spleen and lymph nodes. Interestingly, several
quantitative and qualitative and organ-speciﬁc differences were
also observed (Weihe et al., 1991) with these differences postu-
lated to vary due to the vascularity of the tissue/organ investi-
gated, suggesting both localised and global factors inﬂuence the
niche and hence cell fate and function.
PGs are credited, in one system or another, with controlling:
cell division, adhesion, spreading, migration, chemoattraction,
axon guidance, matrix assembly, lipoprotein uptake, extracellular
proteolysis, and viral entry (Lander and Selleck, 2000). Since
PGs are located at strategic sites in various tissues, it is likely
they inﬂuence stem cell fate decisions through their localisation
at both the cell surface and within the ECM. Indeed, various
ligands are known to bind selectively to speciﬁc HS sequences,
including FGF-1, FGF-2, TGF-β, and platelet factor 4 (Lindahl
et al., 1998). Cell surface HS may regulate cell differentiation
through multiple mechanisms including immobilisation of the
ligand; increasing its local concentration; altering its conﬁrmation;
presentation of the ligand to a signalling receptor; or otherwise
modifying the molecular encounters between ligands and
receptors. The overall effect is usually to enhance receptor activa-
tion at low ligand concentrations (Carey, 1997) allowing the
reactants to encounter each other at a much greater rate
than they could in solution. HS can also enhance peptide diffusion,
establish concentration gradients, and accelerate encounters
even for soluble factors for which they do not have high afﬁnity
(Lander, 1998). The effects of cell surface HS vary dependant
upon the relative abundance of the HS chain and reactants,
relative afﬁnities and the size and nature of the HS chain
(Bernﬁeld et al., 1999). We have previously demonstrated that
increased glypican-3 correlates with differentiation of MC3T3 pre-
osteoblast cells toward the osteoblast lineage and is associated
with N- and O-HS speciﬁc sulfation (Haupt et al., 2009). HS has
also been shown to be involved in axon guidance through
modulation of FGF signalling (reviewed in Yamaguchi, 2001).
HSPGs therefore, not only provide a storage depot for heparin-
binding molecules in the cell microenvironment, but also decisi-
vely regulate their accessibility, function and mode of action
(Vlodavsky et al., 2011).
The niche, PGs and the neural linage
Several reports have related the variable sulfation patterns of
HS with roles in differentiation (Habuchi et al., 2004; Haupt et al.,
2009; Lindahl et al., 1998) or transformation of cells in culture
(Jayson et al., 1998; Safaiyan et al., 1998). Despite the lack of a
uniﬁed picture, the data demonstrate that the structure of HS
produced by a single cell may be modulated because of distinct
stimuli (Kjellen et al., 1983). With the ECM and its constituents
able to modulate cellular phenotypes, cell–cell interactions and
signalling cascades, the complexity of HS and CS chains, deter-
mined by the variety in length and sulfation patterns, are thought
to give these proteins their niche speciﬁcity, that is, speciﬁc
functions in speciﬁc tissues (Haupt et al., 2009).
HSPGs bind FGFs, Wnts and BMPs, to mediate proliferation and
differentiation of MSCs as well as progenitors in lineages such as
osteoprogenitors (Cool and Nurcombe, 2006; Dombrowski et al.,
2009; Ling et al., 2006). The Wnt proteins are cysteine-rich
secreted glyco-lipoproteins that regulate development, cell pro-
liferation, motility, cell fate and cell polarity (Lee et al., 2006).
Wnts and their downstream signalling pathways have been
extensively examined and demonstrated to play an important role
in the self-renewal and differentiation of MSCs (Ling et al., 2009).
Wnt pathway activity is regulated by intracellular signalling
components as well as extracellular factors speciﬁcally the HSPGs
where through variation in binding afﬁnity, HS ﬁne-tunes the
access of Wnts to their receptors (frizzled) regulating several
developmental processes (Perrimon and Bernﬁeld, 2000). Depen-
dent upon the biological context, the HSPG glypicans either
stimulate or inhibit signalling activity (Filmus et al., 2008). In
addition to their localisation on the cell membrane and in the
extracellular environment, glypicans can also be localised to the
cytoplasm as with glypican-3 in liver cancer cells (Capurro et al.,
2003). Most in vivo evidence indicates the main function of
membrane-attached glypicans is the regulation of Wnt, Hh, FGF
and BMP signalling (Ohkawara et al., 2003; Song et al., 2005);
however, the HS chains on glypicans only partially contribute to
this regulatory role (Capurro et al., 2008; Song et al., 2005). In
addition, glypicans can also be shed into the extracellular envir-
onment where they play a role in the transport of these molecules
during morphogen gradient formation (Akiyama et al., 2008).
Members of the FGF family of growth factors require speciﬁc
heparan sulfate sequences (Guimond et al., 1993), with a single cell
surface PG core protein able to carry either FGF-1 or FGF-2 speciﬁc
HS regions depending on growth factor availability at different
developmental stages (Nurcombe et al., 1993). FGF-2 cannot bind
its ‘high-afﬁnity’ receptors (FGFR-1) nor exert its growth stimula-
tory or differentiation inhibiting actions on cells deﬁcient of
appropriately sulfated HSPGs (Ornitz et al., 1992; Rapraeger
et al., 1991) indicating that FGF-2, its tyrosine kinase receptor
and a cell surface HSPG form a ternary complex before the growth
factor signal is transduced through multimerisation and transpho-
sphorylation inside the cell (Rapraeger et al., 1991).
With members of the syndecan family expressed by all adhesive
cells, these HSPGs augment FGF action in vivo (Elenius and Jalkanen,
1994), where normal cell growth is associated with syndecan-1
upregulation and abrogation of this HSPG suppressing proliferation.
The syndecan-1/FGF growth regulatory interaction has been further
demonstrated in vitrowhere syndecan-1 overexpression abrogated the
growth-stimulatory effect of FGF-1 (Elenius and Jalkanen, 1994). This
may be through presentation of the ligand to the receptor, but it is also
possible that cells deﬁcient in syndecan-1, which anchors them to the
ECM, have an altered morphology and become free to divide and
migrate. Indeed, the mechanisms by which cell surface HS molecules
can affect growth factor-regulated growth control may, in addition to
cell surface level, also include events taking place at the peri-cellular,
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extracellular or intracellular level. Proteolytic cleavage of syndecan
ectodomains enables their translocation to the ECM where they may
have the activities described for matrix HSPGs i.e. to form a reservoir of
FGFs, to control diffusion of FGFs or to protect FGFs from proteolytic
activation (Elenius and Jalkanen, 1994).
Numerous factors have been identiﬁed as important regulators
of neural crest migration including, but not restricted to BMPs and
their antagonists, Wnts, Hox genes, E-cadherin, Ephrins, Eph
receptors, matrix metalloproteinases (MMP) and ECM components
(Christiansen et al., 2000). The mechanisms responsible for direc-
ted migration of subsets of neural crest cells are complex.
Throughout morphogenesis, motile cells undergo changes in
shape, protrusive activity and polarity while exerting a force on
neighbouring cells and tissues to generate structures such as
tubes, rods, sheets and cavities. The ECM plays an important
structural role in these processes by contributing directional cues
in the extracellular microenvironment or by deﬁning tissue
boundaries for branching morphogenesis (Rozario and
DeSimone, 2010). While tissue stiffness imparted by the ECM
plays an important role in morphogenesis, it is clear that tissue
“pliability” and elasticity are also critical (reviewed in Mithieux
and Weiss (2005)). Cells migrate along individual ECM molecules
dependent upon niche speciﬁc migratory behaviours and require-
ments. Proteases from both the MMP and ADAM families have
been identiﬁed in localised degradation of the ECM to enable cell
migration during neural crest formation (Alfandari et al., 2001),
and although both these molecular families are known to degrade
ECM components, their substrates also include components of
signalling pathways such as various growth factor receptors, Eph/
Ephrins, notch and delta (Rozario and DeSimone, 2010).
Neurogenesis is mediated by several growth factors and mor-
phogens through molecular interactions at the cell surface, which
may be modulated by PG interactions. There is strong evidence
that FGF-2 is one of the crucial growth factors utilised by NSCs for
proliferation and differentiation (Powell et al., 1991). FGF-2 reg-
ulates the fate of NSC progenies with low FGF-2 concentrations
shown to predominantly generate neurons while high FGF-2
concentrations generate glial cells (Qian et al., 1997). The HSPG
perlecan, secreted into extracellular spaces, is a potent co-receptor
for FGF-2 signalling suggesting a role for this HSPG in the
modulation of FGF-2 activity during neurogenesis (reviewed in
Yamaguchi (2001)). Other HSPGs have also been reported to be
involved in neural differentiation and development. In culture,
NSCs have been shown to express glypican-4 on their cell surface
with this expression restricted to cells that retain stem cell
properties and expression of glypican-4 ceases once cells commit
to neural differentiation (Hagihara et al., 2000). Glypican-1 and
glypican-2 are expressed in post-mitotic neurons and while
glypican 1 can be found on differentiated neurons late in embryo-
nic development (Litwack et al., 1998), when investigated in vivo in
a rat model, glypican-2 is expressed in axon tracts during the
active axon elongation phase (Ivins et al., 1997; Stipp et al., 1994).
Members of the syndecan family of HSPGs are also expressed in
developing brains, with syndecan-2 expressed during dendritic
spine morphogenesis and syndecan-3 expressed in developing
axon tracts (reviewed in Yamaguchi (2001)). These examples
demonstrate function and niche speciﬁcity for HSPGs in the neural
niche. What has yet to be fully investigated is the role of PGs in
neural lineage fate determination, and if and how this role can be
modulated or inﬂuenced.
PGs and hMSCs as a model for the repair of brain damage
Protocols for the differentiation of MSCs into neurons and glial
cells in vitro and in vivo involve either direct differentiation to
neural cell types or conversion to NSC-like spheres prior to
terminal neuronal differentiation (Alexanian, 2010; Hermann
et al., 2004). Nagai et al. (2007) showed in vitro differentiation of
MSCs to neural cell types was characterised by gene expression of
NSC markers (nestin and Musashi1), neurons (neuroﬁlament
protein, synapsin and MAP2), astrocytes (GFAP) and oligodendro-
cytes (Myelin basic protein, MBP) by Q-PCR. Immunocytochemical
localisation of nestin (NSC), neuroﬁlament protein and β-tubulin
III (neurons), GFAP (astrocytes) and galactocerebroside (oligoden-
drocytes) conﬁrmed differentiation into neural cells (Nagai et al.,
2007). Neural stem cell marker panels are commonly used to
conﬁrm stemness using markers of pluripotency. For NSCs, these
panels include markers for each of the three neural lineages:
neuronal, astrocyte and oligodendrocyte. An example of immuno-
cytochemistry analysis for speciﬁc neural markers to conﬁrm
lineage potential of hMSCs at different phases of growth is shown
(Table 2; Fig. 3). Cells are stained positive for nestin, Sox2, MAP2,
GFAP and O1, conﬁrming the neural lineage potential of hMSCs at
early growth phases. As expected, the gradual increase in neural-
associated gene expression in hMSCs is accompanied by morpho-
logical and marker speciﬁc changes associated with the neural
phenotype (Fig. 4). The use of substrates conducive to differentia-
tion towards the neural lineage such as Geltrex™, along with
different media supplements between basal growth media and
differentiation media are commonly used for the in vitro differ-
entiation of neural cells from hMSCs. With speciﬁc culture condi-
tions identiﬁed to differentiate hMSCs to produce neuronal like
cells positive for a number of neural progenitor and mature neural
cell markers (including Sox2, nestin, A2B5, NCAM, B3T, GFAP,
NeuN and MAP2) (Alexanian, 2010), these cells may provide a
useful tool for the development of models aimed at the repair and
limitation of all types of brain damage.
With PGs found in the matrix of all tissues, including the brain,
current data on the role of PGs in the central nervous system
(CNS) indicate that a great variety of individual PGs exist in the
developing and mature brain. There is increasing evidence that
neural PGs are involved in these developmental events including
cellular proliferation, cellular differentiation, axonal growth,
pathﬁnding, and synaptogenesis (reviewed in (Bandtlow and
Zimmermann, 2000; Margolis and Margolis, 1997)). As with
most PGs, those localised in the brain have highly regulated
spatiotemporal expression during nervous system development
and maturation, suggesting that they are involved in distinct
phases of brain development through multiple interactions
(Oohira et al., 2000). Mammalian nervous system development
involves generation of neurons from NSCs, migration of generated
neurons toward genetically determined locations, extension of
axons and dendrites and establishment of neural connectivity.
There are roles for HSPGs in all of these diverse processes
(Yamaguchi, 2001). For example, neural development involves
molecular interactions on the cell surface and PGs modulate cell
surface molecular interactions through ligand–receptor, cell–cell
or cell–matrix interactions. Much evidence supports the role of
ECM laminins, agrin, collagen, tenascins and PGs in synapse
formation (reviewed in (Dityatev et al., 2010; Matsumoto-Miyai
et al., 2009)).
Table 2
Neural stem cell marker panel: markers representing each neural lineage.
Identiﬁcation Sox 2 Nestin MAP-2 GFAP O1
Pluripotent stem cell þ    
Neural stem cell þ þ   
Neuronal lineage   þ  
Astrocyte lineage    þ 
Oligodendrocyte lineage     þ
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Due to the ectodermal origin of neurons, it is not surprising
that their fate is intimately determined by interactions with the
ECM (Bandtlow and Zimmermann, 2000). With the majority of
PGs in the CNS carrying either CS or HS side chains (Bandtlow and
Zimmermann, 2000) some are constituents of the ECM (e.g.
hyalectans) while others are bound to the cell surface through a
GPI anchor (glypicans); others are intercalated into the cell
membrane by a transmembrane domain (syndecans, NG2). As
detailed above, both in vitro and in vivo, PGs display afﬁnity to a
variety of ligands, including growth factors, adhesion molecules,
matrix components, enzymes and enzyme inhibitors (Bandtlow
and Zimmermann, 2000). The long-term exposure to TNF-α
triggers differentiation of hMSCs into mitotic cells with
neurological-like morphology (Egea et al., 2011) with PGs and
their putative binding partners frequently colocalised during
histological examination of the CNS. Thus PGs appear not only to
function as structural elements supporting cells providing tissue
turgor but also appear to mediate crucial events during brain
development (Bandtlow and Zimmermann, 2000).
Summary
Here we provide evidence supporting the importance of PGs in
the localised cellular microenvironment during hMSC lineage fate
speciﬁcation. PGs contribute to the MSC niche through signalling
pathways, cell–ECM interactions, cell surface molecules and the
ECM. By examining PGs in hMSCs characterised and expanded
Fig. 3. Representative ICC images at Pþ7 for NSC makers (hMSC-2). Cells were incubated in appropriate blocking solutions with primary antibodies overnight. (A) MAP2
(ab36447) 1/200 dilution (B) Merge MAP2 (C) Nestin (ab22035) 1/200 dilution (D) Merge Nestin (E) GFAP (AB5804) 1/250 dilution (F) Merge GFAP (G) Oligodendrocyte
marker O1 1/500 dilution (H) Merge O1. Cells were incubated with secondary antibodies for 2 h at room temperature. FITC (green; 1/1000), CY3 (yellow; 1/1000) and
AlexaFluor 594 (red; 1/500). Fluoroshield mounting medium with DAPI (ab104139) was used to stain nuclei (blue). (I–K) q-PCR expression at Pþ7 (hMSC-1).
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in vitro, we can examine their contribution to speciﬁc cell lineages
as well as the microenvironment during neural differentiation.
This combined with data outlining the central role of HSPGs
within the neural niche during development may provide new
targets and a new model for the examination and repair of
localised brain damage.
References
Akiyama, T., Kamimura, K., Firkus, C., Takeo, S., Shimmi, O., Nakato, H., 2008. Dally
regulates Dpp morphogen gradient formation by stabilizing Dpp on the cell
surface. Dev. Biol. 313, 408–419.
Alexanian, A.R., 2010. An efﬁcient method for generation of neural-like cells from
adult human bone marrow-derived mesenchymal stem cells. Regen. Med. 5,
891–900.
Alfandari, D., Cousin, H., Gaultier, A., Smith, K., White, J.M., Darribere, T., DeSimone,
D.W., 2001. Xenopus ADAM 13 is a metalloprotease required for cranial neural
crest-cell migration. Curr. Biol.: CB 11, 918–930.
Bandtlow, C.E., Zimmermann, D.R., 2000. Proteoglycans in the developing brain:
new conceptual insights for old proteins. Physiol. Rev. 80, 1267–1290.
Bernﬁeld, M., Gotte, M., Park, P.W., Reizes, O., Fitzgerald, M.L., Lincecum, J., Zako, M.,
1999. Functions of cell surface heparan sulfate proteoglycans. Annu. Rev.
Biochem. 68, 729–777.
Bernﬁeld, M., Kokenyesi, R., Kato, M., Hinkes, M.T., Spring, J., Gallo, R.L., Lose, E.J.,
1992. Biology of the syndecans: a family of transmembrane heparan sulfate
proteoglycans. Annu. Rev. Cell Biol. 8, 365–393.
Capurro, M., Wanless, I.R., Sherman, M., Deboer, G., Shi, W., Miyoshi, E., Filmus, J.,
2003. Glypican-3: a novel serum and histochemical marker for hepatocellular
carcinoma. Gastroenterology 125, 89–97.
Capurro, M.I., Xu, P., Shi, W., Li, F., Jia, A., Filmus, J., 2008. Glypican-3 inhibits
Hedgehog signaling during development by competing with patched for
Hedgehog binding. Dev. Cell 14, 700–711.
Carey, D.J., 1997. Syndecans: multifunctional cell-surface co-receptors. Biochem. J.
327, 1–16.
Chen, X.D., 2010. Extracellular matrix provides an optimal niche for the main-
tenance and propagation of mesenchymal stem cells. Birth defects research.
Part C. Embryo Today: Rev. 90, 45–54.
Christiansen, J.H., Coles, E.G., Wilkinson, D.G., 2000. Molecular control of neural
crest formation, migration and differentiation. Curr. Opin. Cell Biol. 12,
719–724.
Conget, P.A., Minguell, J.J., 1999. Phenotypical and functional properties of human
bone marrow mesenchymal progenitor cells. J. Cell. Physiol. 181, 67–73.
Cool, S.M., Nurcombe, V., 2006. Heparan sulfate regulation of progenitor cell fate. J.
Cell. Biochem. 99, 1040–1051.
Cunningham, S.C., Kamangar, F., Kim, M.P., Hammoud, S., Haque, R., Iacobuzio-
Donahue, C., Ashfaq, R., Kern, S.E., Maitra, A., Heitmiller, R.E., Choti, M.A.,
Lillemoe, K.D., Cameron, J.L., Yeo, C.J., Montgomery, E., Schulick, R.D., 2006.
MKK4 status predicts survival after resection of gastric adenocarcinoma. Arch.
Surg. 141, 1095–1099.
Dityatev, A., Seidenbecher, C.I., Schachner, M., 2010. Compartmentalization from
the outside: the extracellular matrix and functional microdomains in the brain.
Trends Neurosci. 33, 503–512.
Dombrowski, C., Song, S.J., Chuan, P., Lim, X., Susanto, E., Sawyer, A.A., Woodruff, M.
A., Hutmacher, D.W., Nurcombe, V., Cool, S.M., 2009. Heparan sulfate mediates
the proliferation and differentiation of rat mesenchymal stem cells. Stem Cells
Dev. 18, 661–670.
Egea, V., von Baumgarten, L., Schichor, C., Berninger, B., Popp, T., Neth, P.,
Goldbrunner, R., Kienast, Y., Winkler, F., Jochum, M., Ries, C., 2011. TNF-alpha
respeciﬁes human mesenchymal stem cells to a neural fate and promotes
migration toward experimental glioma. Cell Death Differ. 18, 853–863.
Elenius, K., Jalkanen, M., 1994. Function of the syndecans – a family of cell surface
proteoglycans. J. Cell Sci. 107, 2975–2982.
Engler, A.J., Sen, S., Sweeney, H.L., Discher, D.E., 2006. Matrix elasticity directs stem
cell lineage speciﬁcation. Cell 126, 677–689.
Erices, A., Conget, P., Minguell, J.J., 2000. Mesenchymal progenitor cells in human
umbilical cord blood. Br. J. Haematol. 109, 235–242.
Fernandez, M., Simon, V., Herrera, G., Cao, C., Del Favero, H., Minguell, J.J., 1997.
Detection of stromal cells in peripheral blood progenitor cell collections from
breast cancer patients. Bone Marrow Transplant. 20, 265–271.
Ferrari, G., Cusella-De Angelis, G., Coletta, M., Paolucci, E., Stornaiuolo, A., Cossu, G.,
Mavilio, F., 1998. Muscle regeneration by bone marrow-derived myogenic
progenitors. Science 279, 1528–1530.
Filmus, J., Capurro, M., Rast, J., 2008. Glypicans. Genome Biol. 9, 224.
Filmus, J., Selleck, S.B., 2001. Glypicans: proteoglycans with a surprise. J. Clin.
Investig. 108, 497–501.
Flanagan, L.A., Rebaza, L.M., Derzic, S., Schwartz, P.H., Monuki, E.S., 2006. Regulation
of human neural precursor cells by laminin and integrins. J. Neurosci. Res. 83,
845–856.
Friedenstein, A.J., Chailakhyan, R.K., Gerasimov, U.V., 1987. Bone marrow osteogenic
stem cells: in vitro cultivation and transplantation in diffusion chambers. Cell
Tissue Kinet. 20, 263–272.
Gregory, C.A., Singh, H., Perry, A.S., Prockop, D.J., 2003. The Wnt signaling inhibitor
dickkopf-1 is required for reentry into the cell cycle of human adult stem cells
from bone marrow. J. Biol. Chem. 278, 28067–28078.
Guimond, S., Maccarana, M., Olwin, B.B., Lindahl, U., Rapraeger, A.C., 1993.
Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct
requirements for FGF-1, FGF-2, and FGF-4. J. Biol. Chem. 268, 23906–23914.
Fig. 4. Phase images of hMSC-2 at Pþ12 and q-PCR expression changes of neural genes corresponding to morphological changes towards neuronal like cells
(A) Geltrex™þMesenchymal Stem Cell Growth Media (MSCGM) (B) Geltrex™þNeural Stem Cell Growth Media (NSCGM; containing FGF2 and EGF). (C) Nestin (D) MAP2
(E) GFAP; black bars, MSCGM; grey bars, NSCGM.
R.K. Okolicsanyi et al. / Developmental Biology 388 (2014) 1–108
Habuchi, H., Habuchi, O., Kimata, K., 2004. Sulfation pattern in glycosaminoglycan:
does it have a code? Glycoconj. J. 21, 47–52.
Hacker, U., Nybakken, K., Perrimon, N., 2005. Heparan sulphate proteoglycans: the
sweet side of development. Nature reviews. Mol. Cell Biol. 6, 530–541.
Hagihara, K., Watanabe, K., Chun, J., Yamaguchi, Y., 2000. Glypican-4 is an FGF2-
binding heparan sulfate proteoglycan expressed in neural precursor cells. Dev.
Dyn.: Off. Publ. Am. Assoc. Anat. 219, 353–367.
Hakuno, D., Fukuda, K., Makino, S., Konishi, F., Tomita, Y., Manabe, T., Suzuki, Y.,
Umezawa, A., Ogawa, S., 2002. Bone marrow-derived regenerated cardiomyo-
cytes (CMG Cells) express functional adrenergic and muscarinic receptors.
Circulation 105, 380–386.
Hancock, J.F., 2006. Lipid rafts: contentious only from simplistic standpoints. Nature
reviews. Mol. Cell Biol. 7, 456–462.
Hardingham, T.E., Fosang, A.J., 1992. Proteoglycans: many forms and many func-
tions. FASEB J.: Off. Publ. Fed. Am. Soc. Exp. Biol. 6, 861–870.
Hass, R., Kasper, C., Bohm, S., Jacobs, R., 2011. Different populations and sources of
human mesenchymal stem cells (MSC): a comparison of adult and neonatal
tissue-derived MSC. Cell Commun. Signal.: CCS 9, 12.
Haupt, L.M., Murali, S., Mun, F.K., Teplyuk, N., Mei, L.F., Stein, G.S., van Wijnen, A.J.,
Nurcombe, V., Cool, S.M., 2009. The heparan sulfate proteoglycan (HSPG)
glypican-3 mediates commitment of MC3T3-E1 cells toward osteogenesis.
J. Cell. Physiol. 220, 780–791.
Haynesworth, S.E., Baber, M.A., Caplan, A.I., 1996. Cytokine expression by human
marrow-derived mesenchymal progenitor cells in vitro: effects of dexametha-
sone and IL-1 alpha. J. Cell. Physiol. 166, 585–592.
Haynesworth, S.E., Goshima, J., Goldberg, V.M., Caplan, A.I., 1992. Characterization
of cells with osteogenic potential from human marrow. Bone 13, 81–88.
Hermann, A., Gastl, R., Liebau, S., Popa, M.O., Fiedler, J., Boehm, B.O., Maisel, M.,
Lerche, H., Schwarz, J., Brenner, R., Storch, A., 2004. Efﬁcient generation of
neural stem cell-like cells from adult human bone marrow stromal cells. J. Cell
Sci. 117, 4411–4422.
Hermann, A., Maisel, M., Storch, A., 2006. Epigenetic conversion of human adult
bone mesodermal stromal cells into neuroectodermal cell types for replace-
ment therapy of neurodegenerative disorders. Expert Opin. Biol. Therapy 6,
653–670.
Hu, E., Tontonoz, P., Spiegelman, B.M., 1995. Transdifferentiation of myoblasts by
the adipogenic transcription factors PPAR gamma and C/EBP alpha. In:
Proceedings of the National Academy of Sciences of the United States of
America, vol. 92, pp. 9856–9860.
Iozzo, R.V., 1998. Matrix proteoglycans: from molecular design to cellular function.
Annu. Rev. Biochem. 67, 609–652.
Ivins, J.K., Litwack, E.D., Kumbasar, A., Stipp, C.S., Lander, A.D., 1997. Cerebroglycan,
a developmentally regulated cell-surface heparan sulfate proteoglycan, is
expressed on developing axons and growth cones. Dev. Biol. 184, 320–332.
Jayson, G.C., Lyon, M., Paraskeva, C., Turnbull, J.E., Deakin, J.A., Gallagher, J.T., 1998.
Heparan sulphate undergoes speciﬁc structural changes during the progression
from human colon adenoma to carcinoma in vitro. J. Biol.Chem. 273, 51–57.
Kjellen, L., Bielefeld, D., Hook, M., 1983. Reduced sulfation of liver heparan sulfate in
experimentally diabetic rats. Diabetes 32, 337–342.
Kolf, C.M., Cho, E., Tuan, R.S., 2007. Mesenchymal stromal cells. Biology of adult
mesenchymal stem cells: regulation of niche, self-renewal and differentiation.
Arthritis Res. Ther. 9, 204.
Kopen, G.C., Prockop, D.J., Phinney, D.G., 1999. Marrow stromal cells migrate
throughout forebrain and cerebellum, and they differentiate into astrocytes
after injection into neonatal mouse brains. Proc. Natl. Acad. Sci. USA 96,
10711–10716.
Kuznetsov, S.A., Friedenstein, A.J., Robey, P.G., 1997. Factors required for bone
marrow stromal ﬁbroblast colony formation in vitro. Br. J.Haematol. 97,
561–570.
Lamoureux, F., Baud'huin, M., Duplomb, L., Heymann, D., Redini, F., 2007. Proteo-
glycans: key partners in bone cell biology. BioEssays: News Rev. Mol. Cell. Dev.
Biol. 29, 758–771.
Lander, A.D., 1998. Proteoglycans: master regulators of molecular encounter?
Matrix Biol.: J. Int. Soc. Matrix Biol. 17, 465–472.
Lander, A.D., Selleck, S.B., 2000. The elusive functions of proteoglycans: in vivo
veritas. J. Cell Biol. 148, 227–232.
Lanzoni, G., Alviano, F., Marchionni, C., Bonsi, L., Costa, R., Foroni, L., Roda, G.,
Belluzzi, A., Caponi, A., Ricci, F., Luigi Tazzari, P., Pagliaro, P., Rizzo, R., Lanza, F.,
Roberto Baricordi, O., Pasquinelli, G., Roda, E., Paolo Bagnara, G., 2009. Isolation
of stem cell populations with trophic and immunoregulatory functions from
human intestinal tissues: potential for cell therapy in inﬂammatory bowel
disease. Cytotherapy 11, 1020–1031.
Lee, P.N., Pang, K., Matus, D.Q., Martindale, M.Q., 2006. A WNT of things to come:
evolution of Wnt signaling and polarity in cnidarians. Semin. Cell Dev. Biol. 17,
157–167.
Lindahl, U., Kusche, M., Lidholt, K., Oscarsson, L.G., 1989. Biosynthesis of heparin
and heparan sulfate. Ann. N. Y. Acad. Sci. 556, 36–50.
Lindahl, U., Kusche-Gullberg, M., Kjellen, L., 1998. Regulated diversity of heparan
sulfate. J. Biol. Chem. 273, 24979–24982.
Lindner, U., Kramer, J., Rohwedel, J., Schlenke, P., 2010. Mesenchymal stem or
stromal cells: toward a better understanding of their biology? Transfus. Med.
Hemother.: Off. Organ Dtsch. Ges. Transfus. Immunhamatol. 37, 75–83.
Ling, L., Murali, S., Dombrowski, C., Haupt, L.M., Stein, G.S., van Wijnen, A.J.,
Nurcombe, V., Cool, S.M., 2006. Sulfated glycosaminoglycans mediate the
effects of FGF2 on the osteogenic potential of rat calvarial osteoprogenitor
cells. J. Cell. Physiol. 209, 811–825.
Ling, L., Nurcombe, V., Cool, S.M., 2009. Wnt signaling controls the fate of
mesenchymal stem cells. Gene 433, 1–7.
Litwack, E.D., Ivins, J.K., Kumbasar, A., Paine-Saunders, S., Stipp, C.S., Lander, A.D.,
1998. Expression of the heparan sulfate proteoglycan glypican-1 in the
developing rodent. Dev. Dyn.: Off. Publ. Am. Assoc. Anat. 211, 72–87.
Mackay, A.M., Beck, S.C., Murphy, J.M., Barry, F.P., Chichester, C.O., Pittenger, M.F.,
1998. Chondrogenic differentiation of cultured human mesenchymal stem cells
from marrow. Tissue Eng. 4, 415–428.
Maeda, N., 2010. Structural variation of chondroitin sulfate and its roles in the
central nervous system. Cent. Nerv. Syst. Agents Med. Chem. 10, 22–31.
Makino, S., Fukuda, K., Miyoshi, S., Konishi, F., Kodama, H., Pan, J., Sano, M.,
Takahashi, T., Hori, S., Abe, H., Hata, J., Umezawa, A., Ogawa, S., 1999.
Cardiomyocytes can be generated from marrow stromal cells in vitro. J. Clin.
Investig. 103, 697–705.
Margolis, R.U., Margolis, R.K., 1997. Chondroitin sulfate proteoglycans as mediators
of axon growth and pathﬁnding. Cell Tissue Res. 290, 343–348.
Matsumoto-Miyai, K., Sokolowska, E., Zurlinden, A., Gee, C.E., Luscher, D., Hettwer,
S., Wolfel, J., Ladner, A.P., Ster, J., Gerber, U., Rulicke, T., Kunz, B., Sonderegger, P.,
2009. Coincident pre- and postsynaptic activation induces dendritic ﬁlopodia
via neurotrypsin-dependent agrin cleavage. Cell 136, 1161–1171.
Mezey, E., Chandross, K.J., Harta, G., Maki, R.A., McKercher, S.R., 2000. Turning
blood into brain: cells bearing neuronal antigens generated in vivo from bone
marrow. Science 290, 1779–1782.
Minguell, J.J., 1993. Is hyaluronic acid the “organizer” of the extracellular matrix in
marrow stroma? Exp. Hematol. 21, 7–8.
Minguell, J.J., Erices, A., Conget, P., 2001. Mesenchymal stem cells. Exp. Biol. Med.
226, 507–520.
Mithieux, S.M., Weiss, A.S., 2005. Elastin. Adv. Protein Chem. 70, 437–461.
Nagai, A., Kim, W.K., Lee, H.J., Jeong, H.S., Kim, K.S., Hong, S.H., Park, I.H., Kim, S.U.,
2007. Multilineage potential of stable human mesenchymal stem cell line
derived from fetal marrow. PloS One 2, e1272.
Nurcombe, V., Ford, M.D., Wildschut, J.A., Bartlett, P.F., 1993. Developmental
regulation of neural response to FGF-1 and FGF-2 by heparan sulfate proteo-
glycan. Science 260, 103–106.
Ohkawara, B., Yamamoto, T.S., Tada, M., Ueno, N., 2003. Role of glypican 4 in the
regulation of convergent extension movements during gastrulation in Xenopus
laevis. Development 130, 2129–2138.
Ohta, S., Suzuki, A., Shimada, M., Kosuga, M., Taga, T., Sugiura, Y., Iwai, M., Miyahira,
Y., Okabe, H., Suzuki, S., et al., 1991. Neuronal differentiation of Ewing's sarcoma
induced by cholera toxin B and bromodeoxyuridine – establishment of Ewing's
sarcoma cell line and histochemical study. Acta Paediatr. Jpn. 33, 428–433.
Oohira, A., Matsui, F., Tokita, Y., Yamauchi, S., Aono, S., 2000. Molecular interactions
of neural chondroitin sulfate proteoglycans in the brain development. Arch.
Biochem. Biophys. 374, 24–34.
Ornitz, D.M., Yayon, A., Flanagan, J.G., Svahn, C.M., Levi, E., Leder, P., 1992. Heparin is
required for cell-free binding of basic ﬁbroblast growth factor to a soluble
receptor and for mitogenesis in whole cells. Mol. Cell. Biol. 12, 240–247.
Perrimon, N., Bernﬁeld, M., 2000. Speciﬁcities of heparan sulphate proteoglycans in
developmental processes. Nature 404, 725–728.
Petitou, M., Herault, J.P., Bernat, A., Driguez, P.A., Duchaussoy, P., Lormeau, J.C.,
Herbert, J.M., 1999. Synthesis of thrombin-inhibiting heparin mimetics without
side effects. Nature 398, 417–422.
Pittenger, M.F., Mackay, A.M., Beck, S.C., Jaiswal, R.K., Douglas, R., Mosca, J.D.,
Moorman, M.A., Simonetti, D.W., Craig, S., Marshak, D.R., 1999. Multilineage
potential of adult human mesenchymal stem cells. Science 284, 143–147.
Powell, P.P., Finklestein, S.P., Dionne, C.A., Jaye, M., Klagsbrun, M., 1991. Temporal,
differential and regional expression of mRNA for basic ﬁbroblast growth factor
in the developing and adult rat brain. Brain research. Mol. Brain Res. 11, 71–77.
Qian, X., Davis, A.A., Goderie, S.K., Temple, S., 1997. FGF2 concentration regulates
the generation of neurons and glia from multipotent cortical stem cells. Neuron
18, 81–93.
Ragni, E., Vigano, M., Parazzi, V., Montemurro, T., Montelatici, E., Lavazza, C., Budelli,
S., Vecchini, A., Rebulla, P., Giordano, R., Lazzari, L., 2013. Adipogenic potential
in human mesenchymal stem cells strictly depends on adult or foetal tissue
harvest. Int. J. Biochem. Cell Biol. 45, 2456–2466.
Rapraeger, A.C., Krufka, A., Olwin, B.B., 1991. Requirement of heparan sulfate for
bFGF-mediated ﬁbroblast growth and myoblast differentiation. Science 252,
1705–1708.
Rapraeger, A.C., Ott, V.L., 1998. Molecular interactions of the syndecan core
proteins. Curr. Opin. Cell Biol. 10, 620–628.
Reading, L., Still, K., Bishop, N., Scutt, A., 2000. Peripheral blood as an alternative
source of mesenchymal stem cells. Bone 26 (Suppl), 9S.
Reyes, M., Verfaillie, C.M., 1999. Turning marrow into brain: generation of glial and
neuronal cells from adult bone marrow mesenchymal stem cells. Blood 94,
377a.
Rosenberg, R.D., Shworak, N.W., Liu, J., Schwartz, J.J., Zhang, L., 1997. Heparan
sulfate proteoglycans of the cardiovascular system. Speciﬁc structures emerge
but how is synthesis regulated? J. Clin. Investig. 100, S67–75.
Rotter, N., Oder, J., Schlenke, P., Lindner, U., Bohrnsen, F., Kramer, J., Rohwedel, J.,
Huss, R., Brandau, S., Wollenberg, B., Lang, S., 2008. Isolation and characteriza-
tion of adult stem cells from human salivary glands. Stem Cells Dev. 17,
509–518.
Rozario, T., DeSimone, D.W., 2010. The extracellular matrix in development and
morphogenesis: a dynamic view. Dev. Biol. 341, 126–140.
R.K. Okolicsanyi et al. / Developmental Biology 388 (2014) 1–10 9
Sadan, O., Melamed, E., Offen, D., 2009. Bone-marrow-derived mesenchymal stem
cell therapy for neurodegenerative diseases. Expert Opin. Biol. Ther. 9,
1487–1497.
Safaiyan, F., Lindahl, U., Salmivirta, M., 1998. Selective reduction of 6-O-sulfation in
heparan sulfate from transformed mammary epithelial cells. Eur. J. Biochem./
FEBS 252, 576–582.
Salmivirta, M., Lidholt, K., Lindahl, U., 1996. Heparan sulphate: a piece of informa-
tion. FASEB J.: Off. Publ. Fed. Am. Soc. Exp. Biol. 10, 1270–1279.
Sasisekharan, R., Ernst, S., Venkataraman, G., 1997. On the regulation of ﬁbroblast
growth factor activity by heparin-like glycosaminoglycans. Angiogenesis 1,
45–54.
Shields, L.E., Andrews, R.G., 1998. Gestational age changes in circulating CD34þ
hematopoietic stem/progenitor cells in fetal cord blood. Am. J. Obstet. Gynecol.
178, 931–937.
Shukla, D., Liu, J., Blaiklock, P., Shworak, N.W., Bai, X., Esko, J.D., Cohen, G.H.,
Eisenberg, R.J., Rosenberg, R.D., Spear, P.G., 1999. A novel role for 3-O-sulfated
heparan sulfate in herpes simplex virus 1 entry. Cell 99, 13–22.
Siena, S., Bregni, M., Brando, B., Ravagnani, F., Bonadonna, G., Gianni, A.M., 1989.
Circulation of CD34þ hematopoietic stem cells in the peripheral blood of high-
dose cyclophosphamide-treated patients: enhancement by intravenous recom-
binant human granulocyte-macrophage colony-stimulating factor. Blood 74,
1905–1914.
Song, H.H., Shi, W., Xiang, Y.Y., Filmus, J., 2005. The loss of glypican-3 induces
alterations in Wnt signaling. J. Biol. Chem. 280, 2116–2125.
Stipp, C.S., Litwack, E.D., Lander, A.D., 1994. Cerebroglycan: an integral membrane
heparan sulfate proteoglycan that is unique to the developing nervous system
and expressed speciﬁcally during neuronal differentiation. J. Cell Biol. 124,
149–160.
Sugahara, K., Kitagawa, H., 2002. Heparin and heparan sulfate biosynthesis. IUBMB
Life 54, 163–175.
Tavassoli, M., Minguell, J.J., 1991. Homing of hemopoietic progenitor cells to the
marrow. Proc. Soc. Exp. Biol. Med. 196, 367–373.
Tkachenko, E., Rhodes, J.M., Simons, M., 2005. Syndecans: new kids on the signaling
block. Circ. Res. 96, 488–500.
Tuan, R.S., 2003. Cellular signaling in developmental chondrogenesis: N-cadherin,
Wnts, and BMP-2. J. Bone Jt. Surg. Am. Vol. 85 (2), 137–141.
Veugelers, M., De Cat, B., Ceulemans, H., Bruystens, A.M., Coomans, C., Durr, J.,
Vermeesch, J., Marynen, P., David, G., 1999. Glypican-6, a new member of the
glypican family of cell surface heparan sulfate proteoglycans. J. Biol. Chem. 274,
26968–26977.
Vlodavsky, I., Beckhove, P., Lerner, I., Pisano, C., Meirovitz, A., Ilan, N., Elkin, M., 2011.
Signiﬁcance of heparanase in cancer and inﬂammation. Cancer Microenviron. 5
(2), 115–132.
Watt, F.M., Hogan, B.L., 2000. Out of Eden: stem cells and their niches. Science 287,
1427–1430.
Weihe, E., Nohr, D., Michel, S., Muller, S., Zentel, H.J., Fink, T., Krekel, J., 1991.
Molecular anatomy of the neuro-immune connection. Int. J. Neurosci. 59, 1–23.
Yamaguchi, Y., 2000. Lecticans: organizers of the brain extracellular matrix. Cell.
Mol. Life Sci.: CMLS 57, 276–289.
Yamaguchi, Y., 2001. Heparan sulphate proteoglycans in the nervous system: their
diverse roles in neurogenesis, axon guidance, and synaptogenesis. Semin. Cell
Dev. Biol. 12, 99–106.
Zimmermann, P., David, G., 1999. The syndecans, tuners of transmembrane
signaling. FASEB J.: Off. Publ. Fed. Am. Soc. Exp. Biol. 13, S91–S100.
da Silva Meirelles, L., Caplan, A.I., Nardi, N.B., 2008. In search of the in vivo identity
of mesenchymal stem cells. Stem Cells 26, 2287–2299.
R.K. Okolicsanyi et al. / Developmental Biology 388 (2014) 1–1010
